P. Démoly

ORCID: 0000-0001-7827-7964
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
Research Areas
  • Allergic Rhinitis and Sensitization
  • Asthma and respiratory diseases
  • Food Allergy and Anaphylaxis Research
  • Drug-Induced Adverse Reactions
  • Contact Dermatitis and Allergies
  • Dermatology and Skin Diseases
  • Respiratory and Cough-Related Research
  • Urticaria and Related Conditions
  • Olfactory and Sensory Function Studies
  • Pharmaceutical studies and practices
  • Pharmacovigilance and Adverse Drug Reactions
  • Chronic Obstructive Pulmonary Disease (COPD) Research
  • Eosinophilic Esophagitis
  • Occupational exposure and asthma
  • Inhalation and Respiratory Drug Delivery
  • Pediatric health and respiratory diseases
  • Delphi Technique in Research
  • Mast cells and histamine
  • Pregnancy and Medication Impact
  • Ocular Surface and Contact Lens
  • Immunodeficiency and Autoimmune Disorders
  • Autoimmune Bullous Skin Diseases
  • Inflammatory mediators and NSAID effects
  • Health and Medical Studies
  • Pneumocystis jirovecii pneumonia detection and treatment

Université de Montpellier
2016-2025

Hôpital Arnaud de Villeneuve
2016-2025

Centre Hospitalier Universitaire de Montpellier
2016-2025

Inserm
2016-2025

Institut Universitaire de Recherche Clinique
1999-2024

Institut national de recherche en informatique et en automatique
2024

Académie Nationale de Médecine
2024

Réseau d'Allergo-Vigilance
2005-2023

Community Farm Alliance
2023

Institut Desbrest d'Epidémiologie et de Santé Publique
2023

Anaphylaxis is a clinical emergency, and all healthcare professionals should be familiar with its recognition acute ongoing management. These guidelines have been prepared by the European Academy of Allergy Clinical Immunology (EAACI) Taskforce on Anaphylaxis. They aim to provide evidence-based recommendations for recognition, risk factor assessment, management patients who are at of, experiencing, or experienced anaphylaxis. While primary audience allergists, these also relevant other...

10.1111/all.12437 article EN Allergy 2014-06-09

When drug reactions resembling allergy occur, they are called hypersensitivity (DHRs) before showing the evidence of either drug-specific antibodies or T cells. DHRs may be allergic nonallergic in nature, with allergies being immunologically mediated DHRs. These typically unpredictable. They can life-threatening, require prolong hospitalization, and necessitate changes subsequent therapy. Both underdiagnosis (due to under-reporting) overdiagnosis an overuse term ‘allergy’) common. A...

10.1111/all.12350 article EN Allergy 2014-02-21

Abstract Skin tests are of paramount importance for the evaluation drug hypersensitivity reactions. Drug skin often not carried out because lack concise information on specific test concentrations. The diagnosis allergy is based history alone, which an unreliable indicator true hypersensitivity.To promote and standardize reproducible testing with safe nonirritant concentrations in clinical practice, E uropean N etwork A cademy llergy C linical I mmunology ( EAACI ) Interest Group Allergy has...

10.1111/all.12142 article EN Allergy 2013-04-25

To cite this article: Bousquet J, Heinzerling L, Bachert C, Papadopoulos NG, PJ, Burney PG, Canonica GW, Carlsen KH, Cox Haahtela T, Lodrup KC, Price D, Samolinski B, Simons FER, Wickman M, Annesi‐Maesano I, Baena‐Cagnani CE, Bergmann Bindslev‐Jensen Casale TB, Chiriac A, Cruz AA, Dubakiene R, Durham SR, Fokkens WJ, Gerth‐van‐Wijk Kalayci O, Kowalski ML, Mari Mullol Nazamova‐Baranova O’Hehir RE, Ohta K, Panzner P, Passalacqua G, Ring Rogala Romano Ryan Schmid‐Grendelmeier Todo‐Bom Valenta...

10.1111/j.1398-9995.2011.02728.x article EN Allergy 2011-11-04
Jean Bousquet Holger J. Schünemann Bolesław Samoliński P. Démoly Carlos E. Baena‐Cagnani and 95 more Claus Bachert С. Бонини LP Boulet Philippe‐Jean Bousquet Jan Brožek Giorgio Walter Canonica Thomas B. Casale Álvaro A. Cruz W. J. Fokkens João Fonseca Roy Gerth van Wijk L. Grouse Tari Haahtela N. Khaltaev Piotr Kuna Richard F. Lockey Kai‐Håkon Carlsen Joaquim Mullol Robert M. Naclerio Robyn E. O’Hehir Ken Ohta S. Palkonen Nikolaos G. Papadopoulos Giovanni Passalacqua R. Pawankar David Price Dermot Ryan F. Estelle R. Simons Alkis Togias David M. Williams Arzu Yorgancıoğlu Osman Yusuf Werner Aberer Mitsuru Adachi Ioana Agache N Aït-Khaled Cezmi A. Akdiş A.C.F. Andrianarisoa Isabella Annesi‐Maesano Ignacio J. Ansotegui I. Baiardini E. D. Bateman Anna Bedbrook Bianca Beghè M. Béji Elisabeth H. Bel A. Ben Kheder Kazi Saifuddin Bennoor Karl‐Christian Bergmann F. Berrissoul T. Bieber Carsten Bindslev‐Jensen Michael S. Blaiss Attilio Boner J. Bouchard Fulvio Braido Christopher E. Brightling A. Bush F. Caballero Moisés A. Calderón Mario Calvo Paulo Augusto Moreira Camargos Luigi Caraballo K. H. Carlsen Warner Carr Alfonso Cepeda Alfredo Cesario Niels H. Chavannes Y. Z. Chen A.M. Chiriac Thierry Perez E. Chkhartishvili Giorgio Ciprandi David Costa Linda Cox Adnan Čustović Ronald Dahl U. Darsow F. de Blay Diana Deleanu Judah A. Denburg P. Devillier T. Didi D. Dokic William K. Dolen H. Douagui R. Dubakiene S. R. Durham Mark S. Dykewicz Yehia El‐Gamal A. El-Meziane R. Emuzyte Alessandro Fiocchi Monica Fletcher Takeshi Fukuda

10.1016/j.jaci.2012.07.053 article EN Journal of Allergy and Clinical Immunology 2012-10-04

Abstract Background Allergen immunotherapy ( AIT ) has been thoroughly documented in randomized controlled trials RCT s). It is the only immune‐modifying and causal treatment available for patients suffering from I g E ‐mediated diseases such as allergic rhinoconjunctivitis, asthma insect sting allergy. However, there a high degree of clinical methodological heterogeneity among endpoints studies on , both subcutaneous sublingual SCIT SLIT ). At present, are no commonly accepted standards...

10.1111/all.12383 article EN Allergy 2014-04-25

Hypersensitivity reactions to betalactams (BLs) are classified as immediate or nonimmediate. The former usually appear within 1 h of drug‐intake and mediated by specific IgE‐antibodies. Nonimmediate those occurring more than after drug‐intake, they can be T‐cell mediated. diagnostic evaluation allergic BLs has changed over the last 5 years, for several reasons. Major minor determinants no longer commercially available skin testing in many countries. In reactions, sensitivity immunoassays is...

10.1111/j.1398-9995.2008.01924.x article EN Allergy 2009-01-21

Background: Skin prick testing is the standard for diagnosing IgE‐mediated allergies. However, different allergen extracts and procedures have been applied by European allergy centres. Thus, it has difficult to compare results from centres or studies across Europe. It was, therefore, crucial standardize harmonize in diagnosis treatment within Aims: The Global Asthma Allergy Network (GA²LEN), with partners collaborating Europe, was a unique position take on this task. current study first...

10.1111/j.1398-9995.2009.02093.x article EN Allergy 2009-09-15

To improve the definition of various clinical patterns patients with drug-induced cutaneous side-effects systemic symptoms, and their possible relationships triggering medication, ultimate goal helping in identification causal drug difficult situations when patient is taking several drugs.Cases associated syndromes related to anticonvulsants (carbamazepine, phenytoin phenobarbitone), minocycline, allopurinol, abacavir nevirapine were collected retrospectively from French Pharmacovigilance...

10.1111/j.1365-2133.2006.07284.x article EN British Journal of Dermatology 2006-04-24

Allergen immunotherapy (AIT) is an effective treatment for allergic rhinoconjunctivitis (AR) with or without asthma. It important to note that due the complex interaction between patient, allergy triggers, symptomatology and vaccines used AIT, some patients do not respond optimally treatment. Furthermore, there are no validated generally accepted candidate biomarkers predictive of clinical response AIT. Clinical management receiving AIT efficacy in randomised controlled trials drug...

10.1111/all.13138 article EN Allergy 2017-02-02
Coming Soon ...